Lobo J, et al. - The prognostic value of Ki67, EZH2, LSD1, and SMYD3 immunoexpression was determined in diagnostic biopsies from a cohort of prostate cancer (PCa) patients with long-term follow-up. It was shown that high Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathologic parameters, independently predicted the outcome in patients with PCa at the time of diagnosis. This finding, in turn, could aid in discriminating indolent from aggressive PCa, thereby improving the treatment selection.